Report #2877285

Received Dec 10, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: 0.3 yrs
State: —
Recovered: Unknown
Vaccinated: Nov 1, 2025
Onset: Nov 1, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
RSV	RSV (AREXVY)	GLAXOSMITHKLINE BIOLOGICALS	UNK	UNK	—

Symptoms (2)

Product administered to patient of inappropriate ageWrong product administered

Symptom narrative

received Arexvy instead of nirsevimab or clesrovimab; This non-serious case was reported by a pharmacist via sales rep and described the occurrence of wrong vaccine administered in a 4-month-old patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. Co-suspect products included NIRSEVIMAB for prophylaxis and CLESROVIMAB for prophylaxis. In NOV-2025, the patient received Arexvy. The patient did not receive NIRSEVIMAB and CLESROVIMAB. In NOV-2025, an unknown time after receiving Arexvy, the patient experienced wrong vaccine administered (Verbatim: received Arexvy instead of nirsevimab or clesrovimab). The outcome of the wrong vaccine administered was not applicable. Additional Information: GSK Receipt Date: 08-DEC-2025 A 4-month-old infant received Arexvy instead of nirsevimab or clesrovimab approximately 3 weeks ago for RSV prevention. The infant has had no obvious adverse events to date.